Sigyn Therapeutics converts $841k debentures to Series B Preferred; extends other debt to 2025

Sigyn Therapeutics, Inc.

Brio Capital converts $220,420 debentures into 292.4 shares of Series B Convertible Preferred Stock.
Osher Capital converts $621,000 debentures into 823.86 shares of Series B Convertible Preferred Stock.
Each Series B share is convertible into 125.63 common shares, subject to anti-dilution adjustments.
Brio and Osher amend additional debentures: maturity extended to March 31, 2025; principal increased to $125k and $316,350 respectively.
Additional automatic conversion of $1,856,566 aggregate debentures into Series B Preferred upon NASDAQ listing.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Sigyn Therapeutics, Inc. amended Debentures with Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC valued at $110,000 and $275,000 (effective 2024-04-10).

Action: amendment
Agreement: notes offering
Counterparty: Brio Capital Master Fund Ltd. and Osher Capital Partners, LLC
Value: $110,000 and $275,000
Effective: 2024-04-10

Exact text from the filing

Brio and Osher agreed to amend an additional $110,000 and $275,000, respectively, of Debentures to extend the maturity dates of such Debentures to March 31, 2025 in return for an increase in principal amount of such Debentures to $125,000 and $316,350

View on SEC.gov

301 material agreements filed in the last 30 days. Browse all material agreements →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-014866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.